Biotechnology News

CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027 Recent deal...

Enables expansion of ongoing vitiligo clinical study to U.S. investigational sitesTopline data anticipated Q4 2027 TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a...

NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), a brain–computer interface (BCI) company, today announced that Konstantinos Alataris, Ph.D., founder and...

Management to outline ‘PolyPid 2030’, the Company’s long-term vision and pipeline strategy Event to feature Warren S. Joseph, DPM, FIDSA, a nationally recognized specialist in lower extremity...

VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...

In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.”NRx was requested to prepare and submit labels with the proprietary name currently under review by...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest...

LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting...

Callio Therapeutics wins Best New ADC Drug Developer at the 13th World ADC Awards and presents on dual-payload ADCs at World ADC San Diego 2026.

EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists.